The use of strontium-90 in the treatment of carcinoma in situ of the conjunctiva.
Four patients with carcinoma in situ were treated with strontium-90 beta ray application. The dose used was 4,500 rads after surgical removal or with small recurrent tumor and 7,000 rads for primary treatment. All patients were disease-free at follow-up periods of 48 to 320 months after treatment. One patient required superficial x-ray treatment for recurrent disease. No serious complications developed with the treatment and no progressive cataracts have occurred.
D000368:Aged; D002278:Carcinoma in Situ / Q000532:radiotherapy*; D003228:Conjunctiva / Q000528:radiation effects*; D005134:Eye Neoplasms / Q000532:radiotherapy*; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D009364:Neoplasm Recurrence, Local / Q000532:radiotherapy*; D011879:Radiotherapy Dosage; D013326:Strontium Radioisotopes / Q000627:therapeutic use*; D013997:Time Factors
D013326:Strontium Radioisotopes